Consequently, the POU2F2/PTPRG-AS1/miR-376c-3p/SLC7A11 axis holds potential as both a novel biomarker and therapeutic target for ferroptosis-mediated cancer therapy in TNBC (Li J. et al., 2024). The gene discussed is PTPRG; the disease is cancer.